

Imam Waked

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7112892/imam-waked-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

5,713
citations

33
h-index

74
g-index

155
ext. papers

7,278
ext. citations

5.6
avg, IF

5.33
L-index

#	Paper	IF	Citations
118	Reply to: "correspondence about "Efficacy and safety of basiliximab".. <i>Annals of Hepatology</i> , 2022 , 27, 100679	3.1	
117	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
116	Case study of hepatitis C virus control in Egypt: impact of access program.. <i>Antiviral Therapy</i> , 2022 , 27, 13596535211067592	1.6	0
115	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
114	Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 1053-1059	5.5	3
113	Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study. <i>Global Health, Science and Practice</i> , 2021 , 9, 187-200	2.8	6
112	Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 57-64	18.8	58
111	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
110	Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers. <i>Clinical and Experimental Immunology</i> , 2021 , 203, 3-12	6.2	3
109	Ravidasvir hydrochloride for genotype 1 hepatitis C treatment. <i>Drugs of Today</i> , 2021 , 57, 199-208	2.5	
108	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 1-8	5.5	1
107	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 925-935	5.3	0
106	Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. <i>Journal of Medical Virology</i> , 2021 , 93, 6750-6759	19.7	7
105	Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1553-1558	2.2	3
104	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020 , 382, 1166-1174	59.2	68
103	Paracentesis-induced circulatory dysfunction: are there albumin alternatives?. <i>Egyptian Liver Journal</i> , 2020 , 10,	1.6	1
102	Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. <i>World Journal of Hepatology</i> , 2020 , 12, 99-107	3.4	2

101	High efficacy of low-dose albumin infusion in the prevention of paracentesis-induced circulatory dysfunction. <i>Egyptian Liver Journal</i> , 2020 , 10,	1.6	1
100	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020 , 72, 198-212	11.2	47
99	Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study. <i>Annals of Hepatology</i> , 2020 , 19, 541-545	3.1	4
98	GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. <i>Liver International</i> , 2020 , 40, 2828-2833	7.9	16
97	What's in a name? Renaming SNAFLD to SMAFLD <i>Liver International</i> , 2020 , 40, 1254-1261	7.9	112
96	High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 907-914	4.2	2
95	Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 16-23 ^{2.2}	2.2	10
94	Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1604-1610	4	7
93	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 454-465	18.8	28
92	HCV treatment with direct acting antivirals improves the insulin sensitivity. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 749-754	5.5	3
91	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 1009-1016	4.2	4
90	Intermediate stage hepatocellular carcinoma: a summary review. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 105-117	5.3	13
89	Direct-acting antiviral drugs improve the female sexual burden associated with chronic HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 919-926	5.5	1
88	Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2019 , 11, 542-552	3.4	11
87	Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. <i>Clinical Liver Disease</i> , 2019 , 14, 203-206	2.2	10
86	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. <i>Immunologic Research</i> , 2019 , 67, 123-133	4.3	4
85	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 135-184	18.8	216
84	Clinical Epidemiology of Hepatitis C Virus 2019 , 149-170		1

83	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. <i>Gut</i> , 2019 , 68, 721-728	19.2	22
82	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. <i>Arab Journal of Gastroenterology</i> , 2018 , 19, 26-32	1.7	6
81	Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofx252	1	16
80	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
79	High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection. <i>Journal of Medical Virology</i> , 2018 , 90, 1841-1847	19.7	6
78	Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians. <i>Archives of Virology</i> , 2018 , 163, 2433-2442	2.6	10
77	Retreatment of hepatitis C virus: can it get any better?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 523-524	18.8	1
76	Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. <i>Journal of Medical Virology</i> , 2018 , 90, 1739-1744	19.7	2
75	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. <i>Journal of Hepatology</i> , 2018 , 68, 691-698	13.4	39
74	Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018 , 68, 814-826	13.4	28
73	Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 207-211	2.2	19
72	Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 421-431	6.1	65
71	Health: redefined. <i>Pan African Medical Journal</i> , 2018 , 30, 292	1.2	7
70	Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). <i>Journal of Hepatocellular Carcinoma</i> , 2018 , 5, 109-119	5.3	9
69	One step closer to elimination of hepatitis C in Egypt. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 665	18.8	16
68	High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. <i>International Journal of Infectious Diseases</i> , 2018 , 75, 109-114	10.5	32
67	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
66	National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 262-267	3.4	99

65	Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 681-687	6.1	54
64	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017 , 116, 448-454	8.7	46
63	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2017 , 7, 83-92	4.1	3
62	Utility of post-liver transplantation MELD and delta MELD in predicting early and late mortality. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 1424-1427	2.2	3
61	Effectiveness of sofosbuvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2017 ,	13.4	9
60	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. <i>Growth Factors</i> , 2017 , 35, 76-87	1.6	26
59	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017 , 37, 348-353	3.5	3
58	Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 102-110	3.4	22
57	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. <i>Liver International</i> , 2017 , 37, 534-541	7.9	41
56	Reply to Comment on Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion <i>British Journal of Cancer</i> , 2017 , 117, e6	8.7	
55	Hepatitis C treatment: where are we now?. <i>International Journal of General Medicine</i> , 2017 , 10, 39-52	2.3	64
54	Hepatitis C infection in Egypt: prevalence, impact and management strategies. <i>Hepatic Medicine: Evidence and Research</i> , 2017 , 9, 17-25	3.4	83
53	Hepatitis C in Egypt - past, present, and future. <i>International Journal of General Medicine</i> , 2017 , 10, 1-6	2.3	87
52	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Hepatology</i> , 2017 , 22, 1767-1818	4.1	2
51	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 36-44	18.8	50
50	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. <i>Growth Factors</i> , 2016 , 34, 128-40	1.6	24
49	Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis. <i>Journal of Hepatology</i> , 2016 , 64, S772	13.4	3
48	Final Results of the Pyramid 1 Study, a Phase 3 Registrational Trial of Ravidasvir (PPI-668) and Sofosbuvir in HCV Genotype-4 Patients: High Rates of Sustained Viral Clearance in Cirrhotic and Non-Cirrhotic Patients. <i>Journal of Hepatology</i> , 2016 , 64, S770	13.4	4

47	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. <i>Human Immunology</i> , 2016 , 77, 667-673	2.3	31
46	Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 2093-7	1.7	4
45	Khat-induced liver injuries: A report of two cases. <i>Arab Journal of Gastroenterology</i> , 2016 , 17, 45-8	1.7	4
44	Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. <i>Archives of Virology</i> , 2015 , 160, 1741-50	2.6	9
43	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , 2015 , 9, 251-7	8.8	13
42	Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. <i>Archives of Virology</i> , 2015 , 160, 2833-7	2.6	12
41	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015 , 64, 948-56	19.2	90
40	Long-term effect of mass chemotherapy of <i>Schistosoma mansoni</i> on infection rate and diagnosis accuracy. <i>International Journal of Infectious Diseases</i> , 2015 , 41, 79-82	10.5	2
39	A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients. <i>Apmis</i> , 2015 , 123, 482-9	3.4	4
38	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5654-62	5.6	7
37	Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 696-706	6.1	52
36	P1351 : An open-label study to evaluate the efficacy and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection in Egypt. <i>Journal of Hepatology</i> , 2015 , 62, S863-S864	13.4	2
35	Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015 , 35 Suppl 1, 27-34	7.9	23
34	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. <i>Medical Oncology</i> , 2015 , 32, 432	3.7	12
33	Recent advances in multidisciplinary management of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015 , 7, 673-87	3.4	67
32	Normal liver stiffness: A study in living donors with normal liver histology. <i>World Journal of Hepatology</i> , 2015 , 7, 1149-53	3.4	9
31	Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 6929-34	1.7	2
30	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 34-59	3.4	271

29	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 5-33	3.4	182
28	Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014 , 90, 823-9	3.2	5
27	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014 , 15, 45-52	1.7	65
26	Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. <i>PLoS ONE</i> , 2014 , 9, e90929	3.7	51
25	Peri-Operative Lactate in Living Donor Liver Transplantation.. <i>Transplantation</i> , 2014 , 98, 789	1.8	
24	Optimal Management of HCV Genotype 4. <i>Current Hepatology Reports</i> , 2014 , 13, 286-294	1	
23	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 60-89	3.4	140
22	Female sexual dysfunction among Egyptian patients with chronic hepatitis C. <i>Journal of Sexual Medicine</i> , 2014 , 11, 768-75	1.1	9
21	Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects. <i>PLoS ONE</i> , 2014 , 9, e101264	3.7	6
20	Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. <i>Journal of Clinical Virology</i> , 2013 , 57, 24-8	14.5	16
19	Prevention of paracentesis-induced circulatory dysfunction. <i>Egyptian Liver Journal</i> , 2013 , 3, 118-125	1.6	4
18	Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012 , 106, 98-103	2	32
17	Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. <i>Hpb</i> , 2011 , 13, 385-90	3.8	19
16	Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. <i>Journal of Proteome Research</i> , 2011 , 10, 1828-36	5.6	81
15	Evaluation of different regimens of oral antibiotics in secondary prevention of spontaneous bacterial peritonitis in cirrhotic patients. <i>Egyptian Liver Journal</i> , 2011 , 1, 69-72	1.6	1
14	Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites. <i>Egyptian Liver Journal</i> , 2011 , 1, 61-68	1.6	1
13	Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). <i>Hepatology International</i> , 2009 , 3, 323-33	8.8	73
12	Diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2009 , 15, 1301-14	5.6	123

11	Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 4300-8	5.6	494
10	Serum islet cell autoantibodies during interferon alpha treatment in patients with HCV-genotype 4 chronic hepatitis. <i>Clinical and Developmental Immunology</i> , 2006 , 13, 11-5		1
9	Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. <i>Scandinavian Journal of Immunology</i> , 2005 , 61, 87-91	3.4	25
8	Band ligation versus medical therapy in prevention of variceal rebleeding: A Randomized controlled study in schistosomal hepatic fibrosis and HCV coinfection. <i>Gastroenterology</i> , 2003 , 124, A663-A664	13.3	2
7	Role of hepatitis C infection in chronic liver disease in Egypt. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002 , 67, 436-42	3.2	89
6	Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patients with biliary obstruction. A randomized controlled trial. <i>American Journal of Gastroenterology</i> , 2000 , 95, 2488-2488	0.7	3
5	Iatrogenic Biliary Injuries: Patterns and Surgical Management. <i>Digestive Surgery</i> , 1997 , 14, 534-539	2.5	2
4	Analysis of long-term endoscopic surveillance during follow-up after variceal sclerotherapy from a 13-year experience. <i>American Journal of Medicine</i> , 1997 , 102, 192-9	2.4	19
3	High prevalence of hepatitis C in Egyptian patients with chronic liver disease. <i>Gut</i> , 1995 , 37, 105-7	19.2	42
2	Biliary complications of Fasciola hepatica: the role of endoscopic retrograde cholangiography in management. <i>Journal of Clinical Gastroenterology</i> , 1995 , 21, 309-11	3	14
1	Experience with interferon in chronic hepatitis B in Egypt. <i>Journal of Chemotherapy</i> , 1990 , 2, 310-8	2.3	16